Tumour Angiogenesis Group

We are examining the effect that different doses of angiogenesis inhibitors exert on blood vessels and the relevance of these effects for anti-angiogenic therapy.

We are investigating how the vesicular transport of VEGF receptors controls VEGF-mediated angiogenesis and the response of tumours to angiogenesis inhibitors.

We are using a variety of in vitro and in vivo approaches to address how the tumour microenvironment impacts on the efficacy of anti-angiogenic therapy.

We are using high-throughput approaches to identify genes that modify sensitivity to angiogenesis inhibitors, the aim being to identify new targets for anti-angiogenic therapy.